Functional Genetics Highlights Progress in the Development of Broad-Spectrum Antiviral at the 22nd International Conference on Antiviral Research

Gaithersburg, MD, May 06, 2009 --(PR.com)-- Functional Genetics, Inc. today announced that two platform presentations and three poster abstracts on progress being made in its broad-spectrum antiviral programs will be presented during the International Conference on Antiviral Research in Miami, FL from May 4 to 7.

“The development of broad-spectrum antivirals is our core area of focus and we are proud to introduce our work.” said Michael Kinch, Ph.D., vice president, research and development. Functional Genetics research scheduled to be presented includes:

"Recruitment of the TSG101/ESCRT-I machinery in host cells by influenza virus: Implications for broad spectrum therapy" as a platform presentation on May 6.

"Identification of a small molecule antiviral with broad-spectrum application to multiple, lethal virus types" as a platform presentation on May 7.

About Functional Genetics, Inc.
Functional Genetics, Inc. (FGI) is a privately-held, development stage biotechnology company, headquartered in Gaithersburg, MD. We use innovative science to develop better medicines to treat or prevent infectious diseases and cancer. Our unique scientific approaches have allowed us to develop novel antiviral drugs that demonstrate beneficial activity against a broad-spectrum of different viruses, including HIV, RSV, Influenza, HBV, HCV and bio-threat pathogens, such as Ebola.

For more information, visit Functional Genetics’ website at www.functional-genetics.com

###